Stereotaxis, Inc. (STXS)

NYSEAMERICAN: STXS · Real-Time Price · USD
2.030
-0.020 (-0.98%)
Nov 20, 2024, 4:00 PM EST - Market closed
-0.98%
Market Cap 172.00M
Revenue (ttm) 25.14M
Net Income (ttm) -22.89M
Shares Out 84.73M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 222,782
Open 2.050
Previous Close 2.050
Day's Range 2.010 - 2.060
52-Week Range 1.500 - 3.290
Beta 1.55
Analysts Strong Buy
Price Target 4.50 (+121.68%)
Earnings Date Nov 11, 2024

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage,... [Read more]

Sector Healthcare
IPO Date Aug 12, 2004
Employees 122
Stock Exchange NYSEAMERICAN
Ticker Symbol STXS
Full Company Profile

Financial Performance

In 2023, Stereotaxis's revenue was $26.77 million, a decrease of -4.89% compared to the previous year's $28.15 million. Losses were -$22.06 million, 12.3% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 121.68% from the latest price.

Price Target
$4.5
(121.68% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physician...

23 hours ago - GlobeNewsWire

Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript

Stereotaxis, Inc. (NYSE:STXS) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial ...

9 days ago - Seeking Alpha

Stereotaxis Reports 2024 Third Quarter Financial Results

ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

9 days ago - GlobeNewsWire

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will p...

4 weeks ago - GlobeNewsWire

Stereotaxis to Present at Upcoming Investor Conferences

ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fi...

2 months ago - GlobeNewsWire

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress

ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its tech...

2 months ago - GlobeNewsWire

Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval

GenesisX was approved in Europe and is set to be approved in the US late this year. The new robot is a giant leap forward in accessibility. Stereotaxis should get MAGiC approved in Europe in October. ...

3 months ago - Seeking Alpha

Stereotaxis, Inc. (STXS) Q2 2024 Earnings Call Transcript

Stereotaxis, Inc. (NYSE:STXS) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kimberly Peery - CFO Conference Call Participants Adam ...

3 months ago - Seeking Alpha

Stereotaxis Reports 2024 Second Quarter Financial Results

ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

3 months ago - GlobeNewsWire

Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX

Latest innovation in Robotic Magnetic Navigation technology supports broad accessibility of robotics for minimally-invasive endovascular surgery GenesisX has obtained CE mark in Europe and has been su...

3 months ago - GlobeNewsWire

Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024

ST. LOUIS, July 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

4 months ago - GlobeNewsWire

Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum “Homi”...

4 months ago - GlobeNewsWire

Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment

ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the f...

6 months ago - GlobeNewsWire

Stereotaxis Receives CE Mark Recertification Under EU's MDR Regulatory Framework

ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has rec...

6 months ago - GlobeNewsWire

Stereotaxis Makes A Strategic Acquisition Bolstering Its Future

Stereotaxis made a strategic acquisition of catheter company Access Point Technologies, which is expected to contribute $5 million in sales in the first 12 months after the acquisition. Access Point w...

6 months ago - Seeking Alpha

First Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic Technology

Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac heart program in Southern Italy.

6 months ago - GlobeNewsWire

Stereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa

Stereotaxis presents innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-quality cardiac ablati

6 months ago - GlobeNewsWire

Stereotaxis, Inc. (STXS) Q1 2024 Earnings Call Transcript

Stereotaxis, Inc. (NYSE:STXS) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Offic...

6 months ago - Seeking Alpha

Stereotaxis Reports 2024 First Quarter Financial Results

ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result...

6 months ago - GlobeNewsWire

Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies

ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has ent...

6 months ago - GlobeNewsWire

Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024

ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will ...

7 months ago - GlobeNewsWire

Major Regulatory Approvals Coming For Stereotaxis In The Next 10 Months

The Magic catheter human trial was successful. All 20 patients had acute success and there were 0 adverse events. Stereotaxis submitted the Magic catheter to EU and US regulators, with expectations of...

9 months ago - Seeking Alpha

Stereotaxis, Inc. (STXS) Q4 2023 Earnings Call Transcript

Stereotaxis, Inc. (NYSE:STXS) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kimberly Peery - CFO Conference Call Participants Frank T...

9 months ago - Seeking Alpha

Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulato...

9 months ago - GlobeNewsWire

Stereotaxis Reports 2023 Full Year Financial Results

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...

9 months ago - GlobeNewsWire